Gynica

Company Overview

Snapshot

Founded in January 2019 by Yotam Hod, Gynica operates with 1–10 employees. The company has raised $4 million across two funding rounds. In March 2024, Gynica announced the First-in-Human Clinical Trial of its novel IntraVag© treatment for Endometriosis.

Business overview

Gynica is a biotech company focused on improving women's health by developing safe, effective, non-hormonal, intra-vaginal therapeutic solutions for Endometriosis. The company's core technology is the proprietary IntraVag© platform, a non-invasive, self-administered drug delivery system. Gynica addresses the significant global market for Endometriosis treatments, serving the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology, Drug Delivery, and Drugs Discovery & Development.

Strategic signal

In March 2024, Gynica announced the initiation of its First-in-Human Clinical Trial for the novel IntraVag© treatment targeting Endometriosis. This milestone signals a critical advancement in the company's product development pipeline, moving its proprietary drug delivery platform closer to market. For investors, this indicates significant progress in validating the efficacy and safety of their non-hormonal solution, potentially de-risking future investment and demonstrating a clear path towards commercialization in the underserved women's health market.

Company Intelligence Q&A

What is Gynica's primary focus?

Gynica is a biotech company dedicated to developing safe, effective, non-hormonal, intra-vaginal therapeutic solutions for women suffering from Endometriosis.

When was Gynica founded?

Gynica was founded in January 2019.

What is the status of Gynica's lead product?

In March 2024, Gynica announced the initiation of the First-in-Human Clinical Trial for its novel IntraVag© treatment for Endometriosis.

What is Gynica's proprietary technology?

Gynica's proprietary technology is the IntraVag© platform, a non-invasive, self-administered drug delivery system designed for therapeutic solutions.

What was a key partnership announced by Gynica in May 2022?

In May 2022, HempStreet partnered with Gynica to develop phytopharma products, as reported by BioVoiceNews. This collaboration aimed to leverage Gynica's expertise in women's health and HempStreet's focus on phytopharmaceutical solutions.